ITRM20030572A1 - Uso di inibitori enzimatici di h-prune per la prevenzione ed il trattamento delle metastasi dei tumori iperesprimenti h-prune. - Google Patents
Uso di inibitori enzimatici di h-prune per la prevenzione ed il trattamento delle metastasi dei tumori iperesprimenti h-prune.Info
- Publication number
- ITRM20030572A1 ITRM20030572A1 IT000572A ITRM20030572A ITRM20030572A1 IT RM20030572 A1 ITRM20030572 A1 IT RM20030572A1 IT 000572 A IT000572 A IT 000572A IT RM20030572 A ITRM20030572 A IT RM20030572A IT RM20030572 A1 ITRM20030572 A1 IT RM20030572A1
- Authority
- IT
- Italy
- Prior art keywords
- prune
- metastases
- tumors
- experienced
- prevention
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5029—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on cell motility
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Physiology (AREA)
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT000572A ITRM20030572A1 (it) | 2003-12-11 | 2003-12-11 | Uso di inibitori enzimatici di h-prune per la prevenzione ed il trattamento delle metastasi dei tumori iperesprimenti h-prune. |
PCT/IT2004/000689 WO2005056043A2 (en) | 2003-12-11 | 2004-12-10 | Use of enzymatic inhibitors of h-prune for the prevention and treatment of the metastases of tumours overexpressing h-prune |
JP2006543723A JP2007513940A (ja) | 2003-12-11 | 2004-12-10 | h−PRUNEを過剰発現する腫瘍の転移を予防及び治療するためのh−PRUNEの酵素阻害剤の使用 |
CN2004800368658A CN1897951B (zh) | 2003-12-11 | 2004-12-10 | h-PRUNE的酶抑制剂在制备预防和治疗过度表达h-PRUNE的肿瘤转移的药物中的应用 |
AU2004296643A AU2004296643B2 (en) | 2003-12-11 | 2004-12-10 | Use of enzymatic inhibitors of h-PRUNE for the prevention and treatment of the metastases of tumours overexpressing h-PRUNE |
ES04806854T ES2389550T3 (es) | 2003-12-11 | 2004-12-10 | Uso de inhibidores enzimáticos de h-PRUNE para la prevención y tratamiento de las metástasis de tumores que sobreexpresan h-PRUNE |
CA002549291A CA2549291A1 (en) | 2003-12-11 | 2004-12-10 | Use of enzymatic inhibitors of h-prune for the prevention and treatment of the metastases of tumours overexpressing h-prune |
EP04806854A EP1699460B1 (en) | 2003-12-11 | 2004-12-10 | Use of enzymatic inhibitors of h-prune for the prevention and treatment of the metastases of tumours overexpressing h-prune |
US10/582,115 US20090118171A1 (en) | 2003-12-11 | 2004-12-10 | Use of enzymatic inhibitors of h-prune for the prevention and treatment of the metastases of tumours overexpressing h-prune |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT000572A ITRM20030572A1 (it) | 2003-12-11 | 2003-12-11 | Uso di inibitori enzimatici di h-prune per la prevenzione ed il trattamento delle metastasi dei tumori iperesprimenti h-prune. |
Publications (1)
Publication Number | Publication Date |
---|---|
ITRM20030572A1 true ITRM20030572A1 (it) | 2005-06-12 |
Family
ID=34674585
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IT000572A ITRM20030572A1 (it) | 2003-12-11 | 2003-12-11 | Uso di inibitori enzimatici di h-prune per la prevenzione ed il trattamento delle metastasi dei tumori iperesprimenti h-prune. |
Country Status (9)
Country | Link |
---|---|
US (1) | US20090118171A1 (it) |
EP (1) | EP1699460B1 (it) |
JP (1) | JP2007513940A (it) |
CN (1) | CN1897951B (it) |
AU (1) | AU2004296643B2 (it) |
CA (1) | CA2549291A1 (it) |
ES (1) | ES2389550T3 (it) |
IT (1) | ITRM20030572A1 (it) |
WO (1) | WO2005056043A2 (it) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITRM20060037A1 (it) | 2006-01-25 | 2007-07-26 | Bio Flag S R L | Inibitori della migrazione cellulare mediata dal complesso tra h-prune e gsk-3 relativi usi nella terapia antitumorale |
WO2010003308A1 (zh) * | 2008-07-10 | 2010-01-14 | 卞化石 | 一氧化氮及其信息传递系统在制备恶性肿瘤靶向治疗药物中的应用 |
CA2795765C (en) | 2010-04-06 | 2020-07-07 | Fred Hutchinson Cancer Research Center | Methods for identifying and using inhibitors of casein kinase 1 epsilon isoform for inhibiting the growth and/or proliferation of myc-driven tumor cells |
EP3778896A1 (en) | 2011-08-09 | 2021-02-17 | Fred Hutchinson Cancer Research Center | Methods and compositions for inhibiting the growth and/or proliferation of myc-driven tumor cells |
WO2014045310A1 (en) * | 2012-09-19 | 2014-03-27 | Massimo Zollo | Pyrimido[5,4-d]pyrimidine or pyrimidine derivatives compounds and uses thereof in the treatment of cancer |
US10676746B2 (en) | 2013-11-22 | 2020-06-09 | Fred Hutchinson Cancer Research Center | Methods for identifying therapeutic targets and treating monitoring cancers |
KR20170007181A (ko) | 2015-07-10 | 2017-01-18 | 3스캔 인크. | 조직학적 염색제의 공간 다중화 |
EP3525788B1 (en) * | 2016-10-11 | 2022-05-25 | Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) | Treatment of synucleinopathies |
CN108624674B (zh) * | 2018-03-30 | 2020-11-24 | 青岛泱深生物医药有限公司 | Krt73作为分子靶标在帕金森诊治中的应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5874285A (en) * | 1996-09-13 | 1999-02-23 | Incyte Pharmaceuticals, Inc. | Polynucleotide encoding a novel human nm23-like protein |
EP1074617A3 (en) * | 1999-07-29 | 2004-04-21 | Research Association for Biotechnology | Primers for synthesising full-length cDNA and their use |
CA2458645A1 (en) * | 2001-08-17 | 2003-04-17 | Incyte Genomics, Inc. | Intracellular signaling molecules |
-
2003
- 2003-12-11 IT IT000572A patent/ITRM20030572A1/it unknown
-
2004
- 2004-12-10 JP JP2006543723A patent/JP2007513940A/ja active Pending
- 2004-12-10 CA CA002549291A patent/CA2549291A1/en not_active Abandoned
- 2004-12-10 ES ES04806854T patent/ES2389550T3/es active Active
- 2004-12-10 CN CN2004800368658A patent/CN1897951B/zh not_active Expired - Fee Related
- 2004-12-10 WO PCT/IT2004/000689 patent/WO2005056043A2/en active Application Filing
- 2004-12-10 EP EP04806854A patent/EP1699460B1/en not_active Not-in-force
- 2004-12-10 AU AU2004296643A patent/AU2004296643B2/en not_active Ceased
- 2004-12-10 US US10/582,115 patent/US20090118171A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN1897951A (zh) | 2007-01-17 |
EP1699460A2 (en) | 2006-09-13 |
CA2549291A1 (en) | 2005-06-23 |
WO2005056043A3 (en) | 2005-07-14 |
US20090118171A1 (en) | 2009-05-07 |
CN1897951B (zh) | 2011-09-28 |
AU2004296643B2 (en) | 2010-09-09 |
ES2389550T3 (es) | 2012-10-29 |
JP2007513940A (ja) | 2007-05-31 |
EP1699460B1 (en) | 2012-06-13 |
AU2004296643A1 (en) | 2005-06-23 |
WO2005056043A2 (en) | 2005-06-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE445614T1 (de) | Phosphatidylinositol 3-kinase inhibitoren | |
NO20053356D0 (no) | Aminindazolderivater og anvendelse derav som kinaseinhibitorer. | |
ITMI991608A0 (it) | Sonda elettrochirurgica per il trattamento di tumori mediante radiofre quenza | |
ATE505471T1 (de) | Azaindol-kinaseinhibitoren | |
ZA200309738B (en) | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same. | |
IS8125A (is) | Kínasólínafleiður til að meðhöndla krabbamein | |
DK2305250T3 (da) | Benzimidazolderivater og anvendelse heraf som proteinkinaseinhibitorer | |
DE60325032D1 (de) | 2-hydroxy-3-heteroarylindole derivate als gsk3 inhibitoren | |
AP2421A (en) | Quinoline derivatives and their use as mycobacterial inhibitors. | |
ZA200507170B (en) | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same | |
AP2003002857A0 (en) | New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors. | |
EA200801301A1 (ru) | ИНГИБИТОРЫ АКТИВНОСТИ Akt | |
NO20041887L (no) | Benzomidazoler anvendelige som proteinkinase-inhibitorer | |
ITMI20001107A0 (it) | Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel | |
ZA200600176B (en) | Combination of SRC kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases | |
IS6918A (is) | Meðferð erfiðra æxla með notkun epóþílon afleiða | |
ATE308325T1 (de) | Triaryl-oxy-aryloxy-pyrimidine-2,4,6-trion derivate als metalloproteinase inhibitoren | |
IS7970A (is) | PDE4-hemlar til að meðhöndla eitlafrumuæxli | |
ITRM20030572A1 (it) | Uso di inibitori enzimatici di h-prune per la prevenzione ed il trattamento delle metastasi dei tumori iperesprimenti h-prune. | |
ITRM20050250A1 (it) | Procedimento ed apparecchio per la rifusione di superfici metalliche. | |
IT1306165B1 (it) | Impiego di inibitori della sostanza p per il trattamento degliadenocarcinomi. | |
EE05263B1 (et) | IL-18 inhibiitorite kasutamine kesknrvissteemi kahjustuste raviks v?i ennetamiseks | |
ATE493390T1 (de) | 2,3-diaryl-pyrazolidine derivate als neurotensin abbauende enzyme-inhibitoren | |
ITRM20020517A0 (it) | Dispositivo magnetico per il trattamento di fluidi. | |
DK1505956T3 (da) | Fremgangsmåde til at forbedre overfladeegenskaberne på farmaceutiske tabletter |